

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



国药集团
SINOPHARM

CHINA TRADITIONAL CHINESE MEDICINE HOLDINGS CO. LIMITED
中國中藥控股有限公司

(Incorporated in Hong Kong with limited liability)
(Stock Code: 570)

**CLARIFICATION ANNOUNCEMENT IN RELATION TO ANNOUNCEMENT OF
ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2019**

Reference is made to the English version of the announcement of annual results for the year ended 31 December 2019 (the “Announcement”) of China Traditional Chinese Medicine Holdings Co. Limited (the “Company”, together with its subsidiaries, the “Group”). Unless defined otherwise, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

The Board would like to clarify an inadvertent clerical error on page 2 in the Announcement regarding “a final dividend” for the year ended 31 December 2019. The amount of the final dividend should be “HK4.76 cents per share (approximately RMB4.34 cents)”.

Save as disclosed above, all other information in the Announcement and its Chinese version shall remain unchanged.

By Order of the Board
China Traditional Chinese Medicine Holdings Co. Limited
ZHAO Dongji
Joint Company Secretary

Hong Kong, 31 March 2020

As at the date of this announcement, the Board comprises twelve Directors, of which Mr. WU Xian, Mr. WANG Xiaochun and Mr. YANG Wenming are executive Directors; Mr. YANG Shanhua, Ms. LI Ru, Mr. YANG Binghua, Mr. WANG Kan and Mr. KUI Kaipin are non-executive Directors; and Mr. XIE Rong, Mr. YU Tze Shan Hailson, Mr. QIN Ling and Mr. LI Weidong are independent non-executive Directors.